Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights a significant overseas licensing deal for the PD1/VEGF dual antibody with Pfizer, exceeding market expectations with a transaction scale of over $1.25 billion upfront payment and potential milestone payments of up to $4.8 billion, along with a double-digit percentage sales share [7] - The company is expected to show substantial revenue growth, with projected revenues reaching RMB 19.1 billion in 2025, representing a year-on-year growth rate of 109.7% [6][8] - The report anticipates a dramatic increase in net profit, forecasting RMB 9.8 billion in 2025, a year-on-year increase of 368.2% [6][8] - The company is expected to maintain a strong market position with core products like Teibiao and Mandi showing robust growth, with Teibiao's sales projected at RMB 5.06 billion in 2024, a 20.4% increase [7] - The report suggests that the company's innovative products and partnerships with various pharmaceutical companies will provide additional revenue growth opportunities [7] Financial Summary - The company's projected operating income for 2025 is RMB 19,102 million, with a gross profit margin of 86.5% [8] - The estimated earnings per share for 2025 is RMB 4.08, with a projected price-to-earnings ratio of 4.37 [6][8] - The report estimates a target market value of approximately RMB 595 billion, equivalent to about HKD 645 billion, based on the company's stable growth and the high elasticity provided by innovative products [7]
三生制药（01530）：PD1/VEGF双抗海外权益授权辉瑞，交易规模超预期